Ingredient or product comparison
TB-500 GHK-Cu Stack Skin Rejuvenation Protocol 2026: Research Outcomes Comparison
The following table compares observed outcomes from published research protocols investigating TB-500 and GHK-Cu monotherapy versus combination stacking for dermal applications in 2026: TB-500 monotherapy (2.5mg 2×/week) Actin polymerization, cell migration, V
This source-based comparison does not add ratings or recommend a winner.
- The following table compares observed outcomes from published research protocols investigating TB-500 and GHK-Cu monotherapy versus combination stacking for dermal applications in 2026:
- TB-500 monotherapy (2.5mg 2×/week)
- Actin polymerization, cell migration, VEGF upregulation
- 35–40% faster than control
- 15–20% increase from baseline
- Moderate (0.4–0.6 on 0–1 scale)
- Fast closure but suboptimal matrix quality. Best for acute injury phases
- GHK-Cu monotherapy (2mg daily SC)
- Copper-dependent collagen synthesis, MMP modulation, antioxidant enzyme activation
- 20–25% faster than control
- 30–35% increase from baseline
- Low (0.2–0.3 on 0–1 scale)
- Strong matrix remodeling but slower migration. Best for remodeling phases
- TB-500 + GHK-Cu stack (2.5mg TB-500 2×/week + 2mg GHK-Cu daily)
- Complementary actin dynamics and collagen synthesis pathways
- 50–55% faster than control
- 45–50% increase from baseline
- Low (0.15–0.25 on 0–1 scale)
- Synergistic effect on both closure speed and matrix quality. Current gold standard in wound research
- Topical GHK-Cu (5mg 2×/day with microneedling)
- Surface-level collagen stimulation, limited dermal penetration
- 10–15% faster than control
- 10–15% increase from baseline
- Low (0.3–0.4 on 0–1 scale)
- Non-invasive but significantly lower bioavailability. Suitable only for superficial applications